2024
Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies
Cani L, Scott S, Joseph N, Hofmeister C, Gupta V, Dhodapkar M, Lonial S, Nooka A, Kaufman J. Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies. Blood 2024, 144: 3311. DOI: 10.1182/blood-2024-206155.Peer-Reviewed Original ResearchRelapsed refractory multiple myelomaGrade 3 infectionLines of therapyChimeric antigen receptor T-cell therapyEpstein-Barr virusIntravenous immunoglobulinCytomegalovirus reactivationFollow-upRisk of infectionInfectious complicationsTreatment of relapsed refractory multiple myelomaMedian age of ptsUsage of intravenous immunoglobulinBispecific antibodiesNext line of therapyEpstein-Barr virus reactivationGrade 3 eventsMedian prior linesMonthly intravenous immunoglobulinGrade 3 neutropeniaT-cell therapyData cut-offRefractory multiple myelomaMedian Follow-UpAssociated with significant risk
2023
Novel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery
Esmaeilzadeh H, Rezaei N, Aminorroaya A, Rayzan E, Shahkarami S, Seyedpour S, Zoghi S, Aryan Z, Somekh I, Rohlfs M, Klein C. Novel DNMT3B Mutation in a Patient with Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome and a Bronchopulmonary Collateral Artery. Endocrine Metabolic & Immune Disorders - Drug Targets 2023, 23: 410-415. PMID: 35996251, DOI: 10.2174/1871530322666220822141722.Peer-Reviewed Original ResearchConceptsRecurrent respiratory infectionsFacial anomaliesDNMT3B mutationsRecurrent infectionsCollateral arteriesFamily historyRespiratory infectionsHistory of recurrent respiratory infectionsAssociated with recurrent infectionsCentromeric instabilityFamily history of consanguinityRare autosomal recessive disorderRecurrent episodes of pneumoniaMonthly intravenous immunoglobulinProphylactic trimethoprim-sulfamethoxazolePrimary immune deficiencyBone marrow studyLow-set earsPatent ductus arteriosusEvaluation of neutropeniaEpisodes of pneumoniaHistory of consanguinityMild facial anomaliesAutosomal recessive disorderSystolic cardiac murmur
2011
Mycophenolate Mofetil and Thrombopoietin Receptor Agonists in the Treatment of Refractory Thrombocytopenia in Patients with Autoimmune Lymphoproliferative Syndrome
Chang L, Price S, Perkins K, Davis J, Aldridge P, Recht M, Kelleher J, Rao V. Mycophenolate Mofetil and Thrombopoietin Receptor Agonists in the Treatment of Refractory Thrombocytopenia in Patients with Autoimmune Lymphoproliferative Syndrome. Blood 2011, 118: 2218. DOI: 10.1182/blood.v118.21.2218.2218.Peer-Reviewed Original ResearchThrombopoietin receptor agonistsTreatment of refractory thrombocytopeniaAutoimmune lymphoproliferative syndromeMycophenolate mofetilStable platelet countIntravenous immunoglobulinPlatelet countReceptor agonistsRefractory thrombocytopeniaYear old manDosing regimensLymphoproliferative syndromeCourse of high dose corticosteroidsTreatment of refractory immune thrombocytopeniaDiscontinuation of mycophenolate mofetilResponse to IVIGInitiation of mycophenolate mofetilRefractory to high-dose corticosteroidsInitiation of eltrombopagMonthly intravenous immunoglobulinNon-malignant lymphadenopathyRefractory immune thrombocytopeniaWeeks of rituximabHigh-dose corticosteroidsHigh dose corticosteroids
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply